Profile data is unavailable for this security.
About the company
Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.
- Revenue in EUR (TTM)53.35m
- Net income in EUR2.95m
- Incorporated1975
- Employees208.00
- LocationLavipharm SAAgias Marinas Street, PeaniaPO Box 59ATHINA 190 02GreeceGRC
- Phone+30 2 106691000
- Fax+30 2 106642310
- Websitehttps://www.lavipharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abeona Therapeutics Inc | 337.03k | 69.39m | 228.76m | 136.00 | 4.53 | 1.53 | 3.21 | 678.75 | 1.11 | 1.11 | 0.0073 | 3.27 | 0.0023 | -- | 0.2478 | 2,941.18 | 46.83 | -62.23 | 52.94 | -78.23 | -122.00 | -- | 20,587.50 | -1,824.21 | 9.53 | -- | 0.1034 | -- | -100.00 | -- | -17.62 | -- | -17.78 | -- |
| Pyridam Farma Tbk PT | 141.14m | -24.12m | 230.65m | 2.34k | -- | 6.29 | -- | 1.63 | -76.90 | -76.90 | 326.28 | 65.22 | 0.4401 | 4.30 | 3.88 | 1,450,964,000.00 | -7.52 | -1.59 | -10.76 | -2.02 | 23.36 | 35.12 | -17.09 | -2.65 | 0.736 | -0.4821 | 0.8735 | -- | 173.59 | 50.70 | -287.52 | -- | 110.52 | -- |
| Evolus Inc | 240.83m | -49.34m | 234.85m | 329.00 | -- | -- | -- | 0.9752 | -0.9125 | -0.9125 | 4.46 | -0.4441 | 1.27 | 4.09 | 6.01 | 860,912.60 | -26.11 | -37.04 | -36.48 | -57.14 | 65.83 | 65.19 | -20.49 | -51.26 | 1.53 | -2.13 | 1.25 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
| Spectral Medical Inc | 1.67m | -25.80m | 235.32m | 29.00 | -- | -- | -- | 140.60 | -0.1455 | -0.1456 | 0.0095 | -0.2375 | 0.331 | 4.43 | 7.03 | 93,275.86 | -510.19 | -135.57 | -- | -711.89 | 56.16 | 55.19 | -1,541.33 | -581.02 | 0.1044 | -0.1904 | -- | -- | 43.05 | -4.43 | 0.7223 | -- | -30.03 | -- |
| Lavipharm SA | 53.35m | 2.95m | 239.20m | 208.00 | 81.31 | 4.27 | 20.57 | 4.48 | 0.0174 | 0.0229 | 0.3159 | 0.3325 | 0.4265 | 1.46 | 3.05 | 261,500.00 | 2.36 | 3.65 | 3.38 | 5.72 | 47.73 | 43.28 | 5.53 | 6.74 | 0.724 | 3.61 | 0.3754 | -- | 3.96 | 9.53 | 333.78 | 10.22 | 31.90 | -- |
| Fennec Pharmaceuticals Inc | 32.68m | -5.85m | 242.30m | 36.00 | -- | -- | -- | 7.41 | -0.2524 | -0.2524 | 1.41 | -0.1601 | 0.7171 | 1.48 | 2.41 | -- | -12.83 | -55.15 | -15.26 | -64.98 | 93.12 | -- | -17.89 | -107.31 | 4.44 | -2.44 | 1.33 | -- | 123.69 | -- | 97.28 | -- | -- | -- |
| Hikal Ltd | 158.08m | 939.76k | 244.96m | 2.06k | 259.88 | 2.20 | 16.29 | 1.55 | 0.8216 | 0.8216 | 137.81 | 96.86 | 0.7065 | 2.01 | 4.59 | 8,239,573.00 | 0.42 | 4.78 | 0.6016 | 7.00 | 55.49 | 48.00 | 0.5945 | 5.71 | 0.5418 | 1.11 | 0.3639 | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Unichem Laboratories Ltd | 205.99m | 27.44m | 245.95m | 3.33k | 8.98 | -- | 6.31 | 1.19 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| Jbm (Healthcare) Ltd | 87.64m | 23.33m | 246.34m | 412.00 | 10.46 | 2.12 | 8.23 | 2.81 | 0.2657 | 0.2657 | 0.9984 | 1.31 | 0.5111 | 3.76 | 5.05 | 2,913,918.00 | 14.09 | 6.57 | 17.00 | 7.83 | 56.76 | 47.82 | 27.56 | 16.60 | 2.41 | -- | 0.2486 | 53.40 | 20.65 | 15.44 | 51.20 | 36.90 | 35.96 | -- |
| Hangzhou Jiuyuan Genetic Biopharm Co Ltd | 159.41m | 15.07m | 249.68m | 1.63k | 14.82 | 1.30 | 12.42 | 1.57 | 0.6472 | 0.6472 | 7.24 | 7.37 | 0.7509 | 1.55 | 2.17 | 959,578.90 | 7.10 | -- | 8.88 | -- | 81.67 | -- | 9.45 | -- | 4.03 | 46.31 | 0.1058 | -- | 6.35 | -- | 15.72 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Praude Asset Management Ltd.as of 31 Dec 2024 | 1.30m | 0.77% |
| Eurobank Asset Management M.F.M.C. SAas of 30 Jun 2025 | 570.00k | 0.34% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 185.98k | 0.11% |
| DFA Australia Ltd.as of 30 Nov 2025 | 1.11k | 0.00% |
